Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-02-26
2009-06-16
Ouspenski, Ilia (Department: 1644)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S279400
Reexamination Certificate
active
07547712
ABSTRACT:
The present invention relates methods for reducing the adverse effects of nicotine. This application describes the use of nicotine carrier conjugates in decreasing the toxic effects of nicotine on a fetus.
REFERENCES:
patent: 6232082 (2001-05-01), Ennifar et al.
patent: 1 512 414 (2005-03-01), None
Keyler et al., Journal of Pharmacology and Experimental Therapeutics, 2003, 305: 587-592.
Keyler et al., “Maternal vaccination against nicotine reduces nicotine distribution to fetal brain in rats,”Journal of Pharmacology and Experimental Therapeutics, May 2003, pp. 587-592; vol. 305, No. 2.
Keyler et al., “Reduced nicotine distribution from mother to fetal brain in rats vaccinated against nicotine: Time course and influence of nicotine dosing regimen,”Biochemical Pharmacology, May 2005, pp. 1385-1395, vol. 69, No. 9.
Nekhayeva et al., “Effects of nicotine-specific antibodies, Nic311 and Nic-igG, on the transfer of nicotine across the human placenta,”Biochemical Pharmacology, Nov. 25, 2005, pp. 1664-1672, vol. 70, No. 11, Pergamon, Oxford GB.
Haustein, “Cigarette smoking, nicotine and pregnancy,”International Journal of Clinical Pharmacology and Therapeutics, Sep. 1999, pp. 417-427, vol. 37, No. 9.
Chen et al., “Effect of prenatal or perinatal nicotine exposure on neonatal thyroid status and offspring growth in rats,”Life Sciences, Jan. 28, 2005, pp. 1249-1258, vol. 76, No. 11, Pergamon Press, Oxford GB.
Malin et al, “Passive immunization against nicotine prevents nicotine alleviation of nicotine abstinence syndrome,”Pharmacology Biochemistry and Behavior, Jan. 2001, pp. 87-92, vol. 68, No. 1.
Lessage, et al., “Current status of immunologic approaches to treating tobacco dependence: vaccines and nicotine-specific antibodies,”The AAPS Journal 2006, Feb. 24, 2006, pp. E65-E75, vol. 8, No. 1.
Foulds et al., “Developments in pharmacotherapy for tobacco dependence: past, present and future,”Drug and Alcohol ReviewJan. 2006, pp. 59-71, vol. 25, No. 1.
Hatsukami et al., “Safety and immunogenicity of a nicotine conjugate vaccine in current smokers,”Clinical Pharmacology&Therapeutics, Nov. 2005, pp. 456-467, vol. 78, No. 5, Mosby-Year Book, St. Louis, MO, US.
Keyler et al., “Changes in maternal and fetal nicotine distribution after maternal administration of monoclonal nicotine-specific antibody to rats,”International Immunopharmacology, Nov. 2006, pp. 1665-1672, vol. 6, No. 11, Elsevier, Amsterdam, NL.
Heading, “NicVAX (Nabi Biopharmaceuticals),”Idrugs: The Investigational Drugs JournalDec. 2003, pp. 1178-1181, vol. 6, No. 12.
Haney et al., “Therapeutic Vaccines for Substance Dependence,”Expert Review of Vaccines, 2004, pp. 11-18, vol. 3, Future Drugs, London GB.
Ennifar Sofiane
Fuller Steve
Terrill James
Winston Scott
Foley & Lardner LLP
Nabi Biopharmaceuticals
Ouspenski Ilia
United States of America as Represented by the Secretary, DHHS O
LandOfFree
Methods for decreasing the toxic effects of nicotine on... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for decreasing the toxic effects of nicotine on..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for decreasing the toxic effects of nicotine on... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4118448